Prime Medicine Corporate Presentation _JPM Corporate Presentation.pdf

1、1Delivering on the promise of Prime EditingCorporate PresentationJanuary 20262This presentation contains forward-looking statements of Prime Medicine,Inc.(Prime,we or our)within the meaning of the Private Securities Litigation Reform Act of 1995,as amended.These forward-looking statements contain in

2、formation about our current and future prospects and our operations,which are based on currently available information.All statements other thanstatements of historical facts contained in this presentation,including statements regarding our strategy,projects and plans are forward-looking statements.

3、In some cases,you can identifyforward-looking statements by terminology such as“aim,”“anticipate,”“assume,”“believe,”“contemplate,”“continue”“could,”“design,”“due,”“estimate,”“expect,”“goal,”“hope,”“intend,”“may,”“might,”“objective,”“opportunity,”“plan,”“predict,”“positioned,”“possible,”“potential,”

4、“project,”“seek,”“should,”“strategy,”“target,”“will,”“would”and other similar expressionsthat are predictions of or indicate future events and future trends,or the negative of these terms or other comparable terminology.These forward-looking statements include,but are not limitedto,express or implie

5、d statements about Primes beliefs and expectations regarding:the potential of Prime Editing to correct the causative mutations of diseases,including CGD,Wilson Disease,CF,and AATD;the continued development and advancement of its AATD and Wilson Disease programs,including the timing of the filing of

6、IND and/or CTA applications in mid-2026 and 1H 2026,respectively,and the timing of initial data for both programs in 2027;the initiation,timing,progress and results of our research and development programs,preclinical studies and future clinicaltrials,including the release of data related thereto;th